Nomination Committee appointed for the Annual General Meeting 2018

The Annual General Meeting of Bactiguard Holding AB (publ) will be held on Wednesday 16 May, 2018 in Botkyrka. 

In accordance with the instructions for the Nomination Committee in Bactiguard Holding AB (publ), the Nomination Committee shall consist of four members. The chairman of the Board of Directors shall contact the three largest shareholders of the Company, in terms of voting power, pursuant to Euroclear Sweden AB’s print out of the share register on 31 August. Each of the three largest shareholders shall be offered the opportunity to, within reasonable time, appoint a member who, together with the chairman of the Board, will constitute the Nomination Committee.

The Nomination Committee for the 2018 AGM in Bactiguard Holding AB (publ) consists of the following members:

Stanley Brodén, Chairman of the Board of Directors
Jan Lombach, appointed by KK Invest AB
Thomas von Koch, appointed by Bactiguard B.V.
Christian Brunlid, appointed by Handelsbanken Fonder AB

The Nomination Committee will make proposals to the AGM 2018 concerning

the election of a Chairman for the AGM, the Chairman and other members of the Board of Directors, as well as auditors. The Nomination Committee will also make proposals regarding remuneration to the Board of Directors, including any separate remuneration for committee work, as well as remuneration to the auditors. Further, the Nomination Committee will make a proposal regarding principles for forming the Nomination Committee for the AGM in 2019.

Shareholders who wish to make proposals to the Nomination Committee can do so by writing to the Nomination Committee under the following address:

Nomination Committee
Bactiguard Holding AB (publ)
Box 15
146 21 Tullinge

Proposals can also be sent by email to the following address:

valberedningen@bactiguard.se

In order for the Nomination Committee to be able to address proposals in a constructive manner, they should have been received by January 19, 2017.

The proposals of the Nomination Committee will be presented in the invitation to the AGM and at the company’s website.

For further information, please contact:

Cecilia Edström, CFO, cell phone: +46 72 226 23 28

About Bactiguard

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection protection solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner CR Bard, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 60 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about how Bactiguard saves lives on www.bactiguard.com


About Us

Bactiguard is a Swedish medtech company with a global presence, offering a solution that prevents healthcare associated infections caused by medical devices. By preventing infections, we contribute to a reduced use of antibiotics and the spread of multi-resistant bacteria, which is a growing problem worldwide. We save lives, increase patient safety and significantly reduce the cost for the healthcare and society. Our technology is well-proven, safe and tissue friendly and consist of a thin layer of noble metals that prevents bacterial growth. The coating can be applied on almost all medical devices. Bactiguard-coated urinary catheters are market leading in the US and Japan and the company has also its own product portfolio consisting of foley catheters, central venous catheters and endotrachealtubes. Bactiguard is a growth company, focused on markets in Europe, Middle East, Asia and Latin America. The company has about 70 employees worldwide, mainly at the headquarters in Stockholm and the production facility in Malaysia and is listed on Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com